German pharmaceutical firm Bayer plans to restructure its diagnostic business by selling its molecular imaging unit, according to a September 16 report in the German issue of the Financial Times.
Bayer is also developing plans to merge the remainder of its diagnostic business into its Medical Care division, according to the report. The diagnostic business segment includes products such as contrast agents Magnevist and Ultravist.
Bayer's molecular imaging business currently is in final clinical trials for its florbetaben PET imaging agent to diagnose Alzheimer's disease.
According to the report, the company has notified approximately 100 employees who could be affected by the potential transaction.
A Bayer HealthCare spokesperson in the U.S. declined to comment on the report to AuntMinnie.com.
